# US 2021/0069148 A1 · Gingko diterpene lactone composition

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0069148 A1
- Document ID: US20210069148A1
- Status: Published application
- Kind: A1
- Application number: 16/771,677
- Filed: 2018-11-13
- Published: 2021-03-11
- Earliest claimed: 2017-12-29
- Assignees: Jiangsu Kanion Pharmaceutical Co., Ltd.
- Applicants: Jiangsu Kanion Pharmaceutical Co., Ltd.
- Inventors: Wei XIAO; Xiujuan CHANG; Enli ZHOU; Xiaodong KANG; Yongxiang WANG; Hanfei HU; Yun WU; Zhenzhong WANG; Chenfeng ZHANG
- Web page: https://patentgrep.com/patent/US20210069148A1

## CPC

- A61K 31/365: Lactones
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K 36/16: Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A Gingko diterpene lactone composition is provided. The extract can lower the neurological function score of a cerebral ischemia-reperfusion rat, reduce the cerebral ischemia area and the water content after brain tissue edema, improve SOD activity, and decrease the MDA content. The composition can inhibit rabbit platelet aggregation induced by PAF and ADP inducers at different time points so as to reduce the maximum aggregation rate. In addition, experiments show that the effect of each monomer compound in the Gingko diterpene lactone composition is significantly increased at certain proportion.

## Claims

### Claim 1

A Gingko diterpene lactone composition, comprising, by weight: 32-36% of GA, 55-60% of GB, and 2.2-3.6% of GK, and the weight ratio of the GB to the GK is 18-22:1.

### Claim 2 (depends on 1)

The composition according to claim 1, wherein the content of the GA is 32-34%, and/or the content of the GB is 56-58%, and/or the content of the GK is 2.4-3.4%.

### Claim 3 (depends on 1)

The composition according to claim 1, comprising, by weight: 33.5-35.2% of GA, 56.1-60.1% of GB, and 2.6-3.0% of GK, wherein the weight ratio of the GB to the GK is 20.0-21.5:1.

### Claim 4 (depends on 1)

A Gingko diterpene lactone preparation containing the composition according to claim 1, wherein the preparation further comprises pharmaceutically acceptable excipients.

### Claim 5 (depends on 1)

A Gingko diterpene lactone injection containing the composition according to claim 1.

### Claim 6 (depends on 5)

The injection according to claim 5, wherein the injection is in a dose of 1 ml or 5 ml or 10 ml, containing 5±0.5 mg or 25±0.5 mg or 50±0.5 mg of the Gingko diterpene lactone composition, respectively.

### Claim 7 (depends on 5)

The injection according to claim 5, further containing meglumine and sodium chloride, wherein the weight ratio of the Gingko diterpene lactone composition to meglumine to sodium chloride is (2-8):(2-8):(4-12).

### Claim 8 (depends on 1)

The application of the composition according to claim 1 in the preparation of a drug for preventing and treating stroke.

### Claim 9 (depends on 1)

The application of the composition according to claim 1 in the preparation of a drug for inhibiting platelet aggregation.

### Claim 10 (depends on 1)

The application of the composition according to claim 1 in the preparation of a neuroprotective drug.

### Claim 11 (depends on 2)

A Gingko diterpene lactone preparation containing the composition according to claim 2, wherein the preparation further comprises pharmaceutically acceptable excipients.

### Claim 12 (depends on 3)

A Gingko diterpene lactone preparation containing the composition according to claim 3, wherein the preparation further comprises pharmaceutically acceptable excipients.
